Abstract
Introduction
Vancomycin, a commonly prescribed antibiotic particularly in the setting of multi-drug resistant infections, is limited by its nephrotoxicity. Despite its common occurrence, much remains unknown on the clinicopathologic profile as well as the pathogenesis of vancomycin nephrotoxicity. Clinical studies included patients often with severe comorbidities and concomitant polypharmacy confounding the causal pathogenesis. Animal models cannot recapitulate this complex clinical situation. Kidney biopsy was not commonly performed.
Methods
To address this limitation, we studied 36 patients who had renal biopsies for acute kidney injury (AKI) for suspicion of vancomycin nephrotoxicity. Detailed renal biopsy evaluation, meticulous evaluation of clinical profiles, and up-to-date follow-up allowed for a diagnostic categorization of vancomycin nephrotoxicity (VNT) in 25 patients and absence of vancomycin nephrotoxicity (NO-VNT) in 11 patients. For careful comparison of these two groups, we proceeded to compile a clinicopathologic and morphologic profiles characteristic for each group.
Results
Patients with VNT had a characteristic clinical profile including a common clinical background, a high serum trough level of vancomycin, a rapidly developed and severe acute kidney injury, and a recovery of renal function often shortly after discontinuation of vancomycin. This clinical course was correlated with characteristic renal biopsy findings including acute tubulointerstitial nephritis of allergic type, frequent granulomatous inflammation, concomitant and pronounced acute tubular necrosis of nephrotoxic type, and vancomycin casts, in the absence of significant tubular atrophy and interstitial fibrosis. This clinico-pathologic profile was different from that of patients with NO-VNT, highlighting its role in the diagnosis, management and pathogenetic exploration of vancomycin nephrotoxicity
Conclusion
Vancomycin nephrotoxicity has a distinctive morphologic and clinical profile, which should facilitate diagnosis, guide treatment and prognostication, and confer pathogenetic insights.
Publisher
Public Library of Science (PLoS)
Reference24 articles.
1. Richard H Drew, George Sakoulas. Vancomycin: Parenteral dosing, monitoring, and adverse effects in adults–In: UpToDate, TW (Ed), UpToDate, Waltham, MA 2020. (Section Editor David C Hooper, Deputy Editor: Elinor L Baron)
2. Vancomycin and the risk of AKI: Now clearer than Mississippi mud;Thomas D Nolin;Clin J Am Soc Nephrol,2016
3. Vancomycin and the risk of AKI: A systematic review and meta-analysis;Abhisekh Sinha Ray;Clin J Am Soc Nephrol,2016
4. The Nephrotoxicity of Vancomycin;EJ Filippone;Clinical Pharmacology and Therapeutics,2017
5. Vancomycin associated cast nephropathy;Yosu Luque;J Am Soc Nephrol,2017
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Vancomycin;Reactions Weekly;2024-05-18